Efficacy
At the data cutoff for the primary efficacy analysis, progression-free survival in Japan subgroup was longer for the veliparib-throughout arm compared with the control arm (Fig. Investigator-assessed progression-free survival in the veliparib-throughout and control groups for Japanese patients and overall study population. Distributions were estimated using Kaplan–Meier methodology in the intention-to-treat populations of Japanese patients (Copyright © 2022 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society